The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Ligand efficiency as a guide in fragment hit selection and optimization
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl999 · Cited by 2,124
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Dobson, C. M. (2004) · Nature · doi:10.1038/nature03192 · Cited by 1,003
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Erlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Fink, T., & Reymond, J.-L. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci600423u · Cited by 457
Virtual Exploration of the Small‐Molecule Chemical Universe below 160 Daltons
Fink, T., Bruggesser, H., & Reymond, J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462457 · Cited by 353
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Howard, S., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Curry, J., Devine, L. A., Early, T. R., Fazal, L., Gill, A. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800984v · Cited by 333
Ligand Binding Efficiency: Trends, Physical Basis, and Implications
Reynolds, C. H., Tounge, B. A., & Bembenek, S. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701255b · Cited by 319
Fragment-Based Drug Design: How Big Is Too Big?
Hajduk, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060511h · Cited by 265
Card, G. L., Blasdel, L., England, B. P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Ibrahim, P. N., Artis, D. R., Bollag, G., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1059 · Cited by 208
Ligand efficiency and fragment-based drug discovery
Bembenek, S. D., Tounge, B. A., & Reynolds, C. H. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.007 · Cited by 196
Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation
Gill, A. L., Frederickson, M., Cleasby, A., Woodhead, S. J., Carr, M. G., Woodhead, A. J., Walker, M. T., Congreve, M. S., Devine, L. A., Tisi, D., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049575n · Cited by 186
Transforming fragments into candidates: small becomes big in medicinal chemistry
de Kloe, G. E., Bailey, D., Leurs, R., & de Esch, I. J. P. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.03.009 · Cited by 178
Self-citationThe role of molecular size in ligand efficiency
Reynolds, C. H., Bembenek, S. D., & Tounge, B. A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.038 · Cited by 169
Fragment-based screening using X-ray crystallography and NMR spectroscopy
Jhoti, H., Cleasby, A., Verdonk, M., & Williams, G. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.07.010 · Cited by 166
Fragment screening: an introduction
Leach, A. R., Hann, M. M., Burrows, J. N., & Griffen, E. J. (2006) · Molecular BioSystems · doi:10.1039/b610069b · Cited by 163
Fragment-based lead discovery: a chemical update
Erlanson, D. A. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.007 · Cited by 149
Overcoming Roadblocks in Lead Optimization: A Thermodynamic Perspective
Ruben, A. J., Kiso, Y., & Freire, E. (2005) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2005.00314.x · Cited by 133
Simple Size-Independent Measure of Ligand Efficiency
Nissink, J. W. M. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900094m · Cited by 125
Fragonomics: fragment-based drug discovery
Zartler, E. R., & Shapiro, M. J. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.05.002 · Cited by 104
Group Efficiency: A Guideline for Hits‐to‐Leads Chemistry
Verdonk, M. L., & Rees, D. C. (2008) · ChemMedChem · doi:10.1002/cmdc.200800132 · Cited by 87
SAR by NMR: Putting the Pieces Together
Hajduk, P. J. (2006) · Molecular Interventions · doi:10.1124/mi.6.5.8 · Cited by 74
Two ‘Golden Ratio’ indices in fragment-based drug discovery
Orita, M., Ohno, K., & Niimi, T. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.006 · Cited by 55
Gill, A. L., Cleasby, A., & Jhoti, H. (2005) · ChemBioChem · doi:10.1002/cbic.200400188 · Cited by 46
Hit and lead identification: Integrated technology-based approaches
Goodnow, R. A. (2006) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2006.12.009 · Cited by 44
Advances in fragment-based drug discovery platforms
Orita, M., Warizaya, M., Amano, Y., Ohno, K., & Niimi, T. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903317580 · Cited by 30
The role of past events in problem solving.
Goodnow, J. J., Rubinstein, I., & Shanks, B. L. (1959) · Journal of Experimental Psychology · doi:10.1037/h0044507 · Cited by 5
The art and practice of structure-based drug design: A molecular modeling perspective
(1996) · doi:10.1002/(sici)1098-1128(199601)16:1<3::aid-med1>3.0.co;2-6
Cited by
Key Topics in Molecular Docking for Drug Design
Torres, P. H. M., Sodero, A. C. R., Jofily, P., & Silva-Jr, F. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184574 · Cited by 641
AMDock: a versatile graphical tool for assisting molecular docking with Autodock Vina and Autodock4
Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A., & Moreno, E. (2020) · Biology Direct · doi:10.1186/s13062-020-00267-2 · Cited by 392
Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design
Chen, L., Zhuang, C., Lu, J., Jiang, Y., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00057 · Cited by 33
Metadata
- Authors
- Schultes, S., de Graaf, C., Haaksma, E. E. J., de Esch, I. J. P., Leurs, R., & Krämer, O.
- Venue
- Drug Discovery Today: Technologies
- Publisher
- Elsevier BV
- Published
- 2010
- Volume
- 7
- Issue
- 3
- Pages
- e157-e162
- ISSN
- 1740-6749 (ISSN-L)
- OpenAlex
- W2031242198
- Cited by
- 252
- References
- 42
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.